Cargando…

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes

Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the tot...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Allen B., Kuroda, Akio, Matsuhisa, Munehide, Hobbs, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960276/
https://www.ncbi.nlm.nih.gov/pubmed/27457238
http://dx.doi.org/10.1007/s11892-016-0772-0
_version_ 1782444499881951232
author King, Allen B.
Kuroda, Akio
Matsuhisa, Munehide
Hobbs, Todd
author_facet King, Allen B.
Kuroda, Akio
Matsuhisa, Munehide
Hobbs, Todd
author_sort King, Allen B.
collection PubMed
description Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII.
format Online
Article
Text
id pubmed-4960276
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-49602762016-08-08 A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes King, Allen B. Kuroda, Akio Matsuhisa, Munehide Hobbs, Todd Curr Diab Rep Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor) Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII. Springer US 2016-07-25 2016 /pmc/articles/PMC4960276/ /pubmed/27457238 http://dx.doi.org/10.1007/s11892-016-0772-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)
King, Allen B.
Kuroda, Akio
Matsuhisa, Munehide
Hobbs, Todd
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title_full A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title_fullStr A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title_full_unstemmed A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title_short A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
title_sort review of insulin-dosing formulas for continuous subcutaneous insulin infusion (csii) for adults with type 1 diabetes
topic Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960276/
https://www.ncbi.nlm.nih.gov/pubmed/27457238
http://dx.doi.org/10.1007/s11892-016-0772-0
work_keys_str_mv AT kingallenb areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT kurodaakio areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT matsuhisamunehide areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT hobbstodd areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT kingallenb reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT kurodaakio reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT matsuhisamunehide reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes
AT hobbstodd reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes